Nov.18, 2014 | By Alec
3D bioprinting company Organovo today announced the full commercial release of the exVive3DTM Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.
Cross-section of multi-cellular bioprinted human liver tissue, stained with hematoxylin & eosin (H&E)
The exVive3D Liver Models are created using Organovo's proprietary 3D bioprinting technology that builds functional living tissues containing precise and reproducible architecture. The process is somewhat like an inkjet printer, arraying the cells into tissue about 20 cells thick.The exVive3D tissue consists of primary human hepatocytes, stellate, and endothelial cell types, which are found in native human liver. The tissues are functional and stable for at least 42 days, which enables assessment of drug effects over study durations that well beyond those offered by industry-standard 2D liver cell culture systems.
On November 16, 2014, Dr. Deb Nguyen, the Director of R&D at Organovo presented during the Functional Analysis & Screening Technologies (FAST) Congress, held November 16-19th in Boston, MA. Dr. Nguyen shared several new pieces of data highlighting the functionality of the Company's ExVive3D bioprinted liver tissues, including the first demonstration of the ability of Organovo exVive3D Human Liver Tissues to be used in studying metabolism of drugs, excellent donor to donor reproducibility of liver tissue performance, and the demonstration of additional methods allowing the study of two specific mechanisms of drug injury.
Organovo has shown that exVive3D Liver Models produce important liver proteins including albumin, fibrinogen and transferrin, synthesize cholesterol, and possess inducible cytochrome P450 enzymatic activities, including CYP 1A2 and CYP 3A4. The exVive 3D Liver has successfully differentiated between structurally related compounds with known toxic and non-toxic profiles in human beings, and the model has also been employed successfully in the detection of metabolites at extended time points in vitro. Importantly, the configuration of the bioprinted liver tissues enables both biochemical and histologic data to be collected so that a customer can investigate compound responses at multiple levels.
The durability and functionality of the 3D liver product enable the assessment of the effects of low dose or repeated dosing regimens across a spectrum of biochemical, molecular, and histologic end points.
Posted in 3D Printing Applications
Maybe you also like:
- LUUV, a 3D printed camera stabilizer for smartphones, now on indiegogo
- Building a toolbox: 3D printed tape measure & dial calipers
- Advertising legend Jacques Séguéla gets 3D printed
- Maker spent 6 months building a 3D printed fully posable action figure
- World's first completely 3D printed, customized Kayak
- Surgeons use 3D printed splint to save another baby's life
- After 23 years of waiting, Somali woman's face restored with 3D printer
- Airbus signs deal with China to make aircraft parts using 3D printers
- Online community offers 9-year-old girl a helping hand with 3D printing
- 'What Will You Print' Series: 3D printed skateboard headlights
- 3D-printed Oreo cookies had the longest line at SXSW
3Ders.org provides the latest news about 3D printing technology and 3D printers. We are now seven years old and have around 1.5 million unique visitors per month.
